A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2013
At a glance
- Drugs Pemetrexed (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2013 Results published in the European Journal of Cancer.
- 01 Oct 2012 Primary endpoint 'Progression-free-survival-duration' has been met according to results presented at the 37th Congress of the European Society for Medical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History